Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: A placebo-controlled clinical trial
Autore:
Geller, DA; Hoog, SL; Heiligenstein, JH; Ricardi, RK; Tamura, R; Kluszynski, S; Jacobson, JG;
Indirizzi:
Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA Eli Lilly & CoIndianapolis IN USA 46285 Ctr, Indianapolis, IN 46285 USA McLean Hosp, Pediat OCD Clin, Belmont, MA 02178 USA McLean Hosp Belmont MA USA 02178 , Pediat OCD Clin, Belmont, MA 02178 USA Phoenix Childrens Hosp, Dept Behav & Dev, Phoenix, AZ USA Phoenix Childrens Hosp Phoenix AZ USA Dept Behav & Dev, Phoenix, AZ USA
Titolo Testata:
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY
fascicolo: 7, volume: 40, anno: 2001,
pagine: 773 - 779
SICI:
0890-8567(200107)40:7<773:FTFODI>2.0.ZU;2-G
Fonte:
ISI
Lingua:
ENG
Soggetto:
DSM-III-R; DOUBLE-BLIND; SCALE; CLOMIPRAMINE; RELIABILITY; CHILDHOOD; PREVALENCE; DEPRESSION; VALIDITY; OCD;
Keywords:
obsessive-compulsive disorder; fluoxetine; selective serotonin reuptake inhibitors;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Citazioni:
29
Recensione:
Indirizzi per estratti:
Indirizzo: Hoog, SL Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA Eli Lilly & Co Indianapolis IN USA 46285 ianapolis, IN 46285 USA
Citazione:
D.A. Geller et al., "Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: A placebo-controlled clinical trial", J AM A CHIL, 40(7), 2001, pp. 773-779

Abstract

Objective: This study assesses the efficacy and tolerability of fluoxetinein the acute treatment of child and adolescent obsessive-compulsive disorder (OCD) during a 13-week, double-blind, placebo-controlled study. Method: Eligible patients aged 7 to 17 (N = 103) were randomized at a ratio of 2:1 to receive either fluoxetine or placebo. Dosing was initiated at 10 mg daily for 2 weeks, then increased to 20 mg daily. After 4 weeks of treatment. and again after 7 weeks of treatment, nonresponders could have their dosage increased by 20 mg daily, for a maximum possible dosage of 60 mg daily. Primary measure of efficacy was improvement in OCD symptoms as measured by theChildren's Yale-Brown Obsessive Compulsive Scale (CY-BOCS). All analyses were intent-to-treat. Results: Fluoxetine was associated with significantly greater improvement in OCD as assessed by the CY-BOCS (p = .026) and other measures than was placebo. Fluoxetine was well tolerated and had a rate of discontinuation for adverse events similar to that of placebo (p = 1.00). Conclusions: Fluoxetine 20 to 60 mg daily was effective and well tolerated for treatment of OCD in this pediatric population.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/01/20 alle ore 16:53:50